CTIM-76 Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers Company expects to enroll first patient in…
Webcast and Conference Call To be Held Thursday, May 9th, 2024, 8:30 am ETNEW YORK, May 02, 2024 (GLOBE NEWSWIRE)…
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on…
GAITHERSBURG, Md., May 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it…
First long-term data presentation from Parts 1 and 2 of the Phase 1 clinical trial of sudocetaxel zendusortide in solid…
Efforts focused on four areas: access and health equity, workforce and DE&I, community impact and the environment CAMBRIDGE, Mass., May…
TORONTO, May 02, 2024 (GLOBE NEWSWIRE) -- VitalHub Corp. (the "Company" or "VitalHub") (TSX: VHI) (OTCQX:VHIBF) is pleased to announce…
CINCINNATI, May 02, 2024 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “Company”) (NASDAQ: QIPT) (TSX: QIPT), a U.S. based…
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June…
Financing includes new and existing leading healthcare investors Proceeds, along with existing cash and cash equivalents, are expected to extend…